Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 23, 2016. The report details a strategic regulatory milestone regarding the company's immuno-inflammation portfolio, specifically the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for sirukumab.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This document is a current report focused on a specific regulatory event rather than a periodic financial statement.
Material Changes and Developments
- Regulatory Submission: Janssen Biotech, Inc. (JBI), an affiliate of GSK, submitted a BLA to the FDA for a subcutaneous formulation of sirukumab for the treatment of moderately to severely active rheumatoid arthritis (RA).
- Target Population: The application targets adult patients who have failed or are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).
- Formulation: Approval is sought for two presentations: a single-dose prefilled syringe and a single-dose autoinjector.
- Global Context: This U.S. submission follows a regulatory submission to the European Medicines Agency (EMA) announced on September 12, 2016.
Outlook, Management Commentary, and Risks
Management Commentary: Paul-Peter Tak, GSK's Chief Immunology Officer, expressed satisfaction with the progress, noting that approval would provide a new treatment option for patients suffering despite conventional and biologic therapies. The company anticipates the outcome of regulatory reviews with interest.
Clinical Data Support: The submission is supported by a comprehensive Phase III clinical development program involving more than 3,000 patients across five studies (SIRROUND-D, SIRROUND-T, SIRROUND-H, SIRROUND-M, and SIRROUND-LTE). Top-line results for several studies were announced in late 2015 and mid-2016.
Collaboration Structure: Sirukumab is co-developed with Janssen Biologics. GSK holds exclusive commercialization rights in the Americas, while Janssen retains rights for the rest of the world. Global profits are shared equally.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in the company's 2015 Annual Report on Form 20-F. Sirukumab is currently not approved for any indication anywhere in the world.
Key Facts for Investor Verification
- Verify the status of the FDA review process for the sirukumab BLA submitted in September 2016.
- Monitor the upcoming presentation of primary results from the SIRROUND-T and SIRROUND-H studies at scientific congresses.
- Track the progress of the ongoing Phase III study for Giant Cell Arteritis and the planned Phase II study for asthma.
- Review the terms of the 2011 licensing and co-development agreement with Janssen regarding profit sharing and territorial rights.
- Assess the competitive landscape for IL-6 inhibitors in the treatment of rheumatoid arthritis.